Gemin X

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Gemin X sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Gemin X: 11 sponsored US clinical trials, none currently recruiting.

Gemin X sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myelofibrosis, with 1 trials.

Top-decile sponsor footprint

Gemin X ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 67/100

10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

TERMINATED Phase 1

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

NCT00724841
COMPLETED Phase 1

A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)

NCT00682981
COMPLETED Phase 2

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

NCT00684918
COMPLETED Phase 2

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

NCT00427856
COMPLETED Phase 2

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)

NCT00413114
COMPLETED Phase 1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT00407303
COMPLETED Phase 1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer

NCT00405951
COMPLETED Phase 2

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia

NCT00360035
COMPLETED Phase 2

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

NCT00359892
COMPLETED Phase 1

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

NCT00438178
COMPLETED Phase 1

A Phase I/II Study of GX15-070MS in Untreated CLL

NCT00600964

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 5

Therapeutic Areas

Myelofibrosis 1

How the Gemin X early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 10 completed (91%).

Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).

Top condition: Myelofibrosis (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gemin X: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gemin X sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Gemin XAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Gemin X sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gemin X sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gemin X page

11 registered trials is a research-attention snapshot, not an endorsement of Gemin X or any single study.

  • None of Gemin X's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Myelofibrosis is the condition Gemin X studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myelofibrosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gemin X pipeline card: 11 registered trials from official public datasets.Report a data error.